

Journal Pre-proof

GloPID-R report on chikungunya, o'nyong-nyong and Mayaro virus, part 3:
Epidemiological distribution of Mayaro virus

L. Pezzi, A.J. Rodriguez-Morales, C.B. Reusken, G.S. Ribeiro, A.D. LaBeaud, R. Lourenço-de-Oliveira, P. Brasil, M. Lecuit, A.B. Failloux, P. Gallian, T. Jaenisch, F. Simon, A.M. Siqueira, M.G. Rosa-Freitas, A. Vega Rua, S.C. Weaver, J.F. Drexler, N. Vasilakis, de Lamballerie X, on behalf of GloPID-R chikungunya, o'nyong-nyong and Mayaro virus Working Group



PII: S0166-3542(19)30513-3

DOI: <https://doi.org/10.1016/j.antiviral.2019.104610>

Reference: AVR 104610

To appear in: *Antiviral Research*

Received Date: 8 September 2019

Accepted Date: 17 September 2019

Please cite this article as: Pezzi, L., Rodriguez-Morales, A.J., Reusken, C.B., Ribeiro, G.S., LaBeaud, A.D., Lourenço-de-Oliveira, R., Brasil, P., Lecuit, M., Failloux, A.B., Gallian, P., Jaenisch, T., Simon, F., Siqueira, A.M., Rosa-Freitas, M.G., Vega Rua, A., Weaver, S.C., Drexler, J.F., Vasilakis, N., de Lamballerie X, , on behalf of GloPID-R chikungunya, o'nyong-nyong and Mayaro virus Working Group, Boyer, S., Busch, M., Diallo, M., Diamond, M.S., Drebot, M.A., Kohl, A., Neyts, J., Ng, L.F.P., Rios, M., Sall, A., Simmons, G., GloPID-R report on chikungunya, o'nyong-nyong and Mayaro virus, part 3: Epidemiological distribution of Mayaro virus, *Antiviral Research* (2019), doi: <https://doi.org/10.1016/j.antiviral.2019.104610>.

This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

© 2019 Published by Elsevier B.V.

GloPID-R report on chikungunya, o'nyong-nyong and Mayaro virus, part 3: Epidemiological distribution of

Mayaro virus

Pezzi L^{a,b,*}, Rodriguez-Morales AJ^c, Reusken CB^{d,e}, Ribeiro GS^f, LaBeaud AD^g, Lourenço-de-Oliveira R^h, Brasil Pⁱ, Lecuit M^j, Failloux AB^k, Gallian P^l, Jaenisch T^m, Simon Fⁿ, Siqueira AM^o, Rosa-Freitas MG^h, Vega Rua A^p, Weaver SC^q, Drexler JF^{r,s}, Vasilakis N^t, de Lamballerie X^a on behalf of GloPID-R chikungunya, o'nyong-nyong and Mayaro virus Working Group (Boyer S^u, Busch M^v, Diallo M^w, Diamond MS^{x,y,z}, Drebot MA^{aa}, Kohl A^{ab}, Neyts J^{ac}, Ng LFP^{ad}, Rios M^{ae}, Sall A^w, Simmons G^{af})

^a Unité des Virus Émergents (UVE: Aix-Marseille Univ-IRD 190-Inserm 1207-IHU Méditerranée Infection), Marseille, France

^b EA7310, Laboratoire de Virologie, Université de Corse-Inserm, Corte, France

^c Public Health and Infection Research Group, Faculty of Health Sciences, Universidad Tecnológica de Pereira, Pereira, Colombia

^d Centre for Infectious Disease Control, National Institute for Public Health and the Environment (RIVM), Bilthoven, the Netherlands

^e Department Viroscience, Erasmus University Medical Center, Rotterdam, the Netherlands

^f Gonçalo Moniz Institute, Oswaldo Cruz Foundation, and Federal University of Bahia, Salvador, Brazil

^g Department of Pediatrics, Division of Infectious Diseases, Stanford University School of Medicine, Stanford, USA

^h Instituto Oswaldo Cruz-Fiocruz, Laboratório de Mosquitos Transmissores de Hematozoários, Rio de Janeiro, Brazil

ⁱ Instituto Nacional de Infectologia Evandro Chagas - Oswaldo Cruz Foundation, Rio de Janeiro, Brazil

^j Institut Pasteur, Biology of Infection Unit, Inserm U1117, Paris Descartes University, Departement of Infectious Diseases and Tropical Medicine, Necker-Enfants Malades University Hospital, APHP, IHU Imagine, Paris, France

^k Department of Virology, Institut Pasteur, Arboviruses and Insect Vectors Unit, Paris, France

^l Établissement Français du Sang Alpes Méditerranée, Marseille, France

^m Section Clinical Tropical Medicine, Department of Infectious Diseases, Heidelberg University Hospital, Heidelberg, Germany

ⁿ Laveran Military Teaching Hospital, Marseille, France

^o Instituto Nacional de Infectologia Evandro Chagas - Oswaldo Cruz Foundation, Rio de Janeiro, Brazil

^p Laboratory of Vector Control Research, Environment and Health Unit, Institut Pasteur de la Guadeloupe, Guadeloupe

^q Institute for Human Infections and Immunity and Department of Microbiology and Immunology, University of Texas Medical Branch, Galveston, USA

^r Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Institute of Virology, 10117 Berlin, Germany

^s German Centre for Infection Research (DZIF), Germany

^t Department of Pathology, Institute of Human Infection and Immunity, University of Texas Medical Branch, Galveston, USA

^u Medical Entomology Platform, Institut Pasteur du Cambodge, Phnom Penh, Cambodia

^v Blood Systems Research Institute, San Francisco, and Department of Laboratory Medicine, University of California, San Francisco, USA

^w Unité d'Entomologie Médicale, Institut Pasteur de Dakar, Dakar, Senegal

^x Department of Medicine, and The Andrew M. and Jane M. Bursky Center for Human Immunology and Immunotherapy Programs, Washington University School of Medicine, St. Louis, USA

^y Department of Molecular Microbiology, and The Andrew M. and Jane M. Bursky Center for Human Immunology and Immunotherapy Programs, Washington University School of Medicine, St. Louis, USA

^z Department of Pathology and Immunology, and The Andrew M. and Jane M. Bursky Center for Human Immunology and Immunotherapy Programs, Washington University School of Medicine, St. Louis, USA

^{aa} Zoonotic Diseases and Special Pathogens, National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, Canada

^{ab} MRC-University of Glasgow Centre for Virus Research, Glasgow, UK

^{ac} KU Leuven, Department of Microbiology and Immunology, Rega Institute for Medical Research, Laboratory of Virology and Chemotherapy, Leuven, Belgium

^{ad} Singapore Immunology Network, Agency for Science, Technology and Research (A*STAR), Singapore

^{ae} Division of Emerging and Transfusion Transmitted Diseases, Laboratory of Emerging Pathogens, Office of Blood Research and Review, Center for Biologics Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, USA

^{af} Blood Systems Research Institute, San Francisco, USA, and Department of Pathology and Laboratory Medicine, University of California, San Francisco, San Francisco, USA

* Corresponding author

1. Introduction

Mayaro virus (MAYV) is a mosquito-borne alphavirus (family *Togaviridae*), transmitted mainly by *Haemagogus* species in the American continent. The first MAYV strains were isolated from the blood of infected, symptomatic humans in Trinidad and Tobago in 1954 [1]. Since then, MAYV was repeatedly detected in humans and mosquito vectors in Central and Southern America [2, 3]. Two unique reports from Haiti raises the issue of circulation in the Caribbean and requires further confirmatory investigations [4, 5]. MAYV is transmitted by *Haemagogus* species in an enzootic cycle using non-human primates (NHPs) as the main amplification and maintenance hosts, and humans becoming sporadically infected when venturing in or nearby forest habitats. Currently, three MAYV genotypes have been described (namely: D, L and N).

MAYV shares with other arboviruses, in particular the related chikungunya virus (CHIKV), a clinical presentation typically characterized by fever, headache and rash during the acute case, together with a polyarthralgia that can persist for months or even years [2, 6–10]. This makes accurate diagnosis based on clinical presentation difficult and it is expected that cases of MAYV infection are being misdiagnosed and/or underreported because of the massive circulation of CHIKV (or even dengue virus (DENV), Zika virus (ZIKV) and oropouche virus (OROV)) in the Americas in recent decades. Laboratory testing is necessary for differential and confirmed diagnosis. Cross-reactivity between antibodies against MAYV and those against related alphaviruses such as CHIKV exist and can lead to a difficult interpretation of serological results [11, 12].

2. GloPID-R chikungunya (CHIKV), o'nyong-nyong (ONNV) and Mayaro virus (MAYV) Working Group

This work has been accomplished by experts of GloPID-R (Global Research Collaboration for Infectious Disease Preparedness, www.glopid-r.org) chikungunya (CHIKV), o'nyong-nyong (ONNV) and Mayaro virus (MAYV) Working Group. The interest of this group is focused on the natural history, epidemiology and medical management of infection by these viruses, in order to identify knowledge gaps and to propose recommendations for direct future investigations and rectification measures. Here, the experts of the GloPID-R Working Group performed an assessment of the available information regarding the epidemiological distribution of MAYV. This work complements other previous or ongoing reports of the GloPID-R Working

Group on chikungunya, o'nyong-nyong and Mayaro virus epidemiology (submitted paper, under review), diagnosis [10], ecology (submitted paper, under review) and clinics.

3. Sources of data

Data from the first virus isolation until December 2018 were collected, including both acute cases in humans (confirmed by RT-PCR and/or presence of IgM) as well as results of serological studies showing past infections in humans (presence of IgG).

Data on MAYV infections were obtained from health organizations and the peer-reviewed literature concerning all the New World countries.

To identify MAYV cases in humans, firstly we consulted different public health alert systems and websites, including:

- World Health Organization ([WHO](#)) - 'Disease outbreak news (DON)' section
- Program for Monitoring Emerging Diseases ([ProMED](#));
- European Centre for Disease Prevention and Control ([ECDC](#)) through 'Communicable disease threats report (CDTR)';
- Institute of health of each American country, through periodic bulletins on viral infections (when available).

A comprehensive review of literature on [PubMed](#) was conducted using the search terms 'mayaro virus' and the name of each American and Caribbean country. Finally, viral sequences available in [GenBank](#) were checked, in order to assess the countries where MAYV-positive human samples were collected. The lineage of MAYV strains (D, L or N) is indicated in the Tables 1-5 of Supplementary data according to information present in GenBank or in articles linked to the viral sequence; otherwise, it was defined through phylogenetic reconstruction.

In the article and in Supplementary data we reported details about MAYV detection: number of cases, year, localization and technique(s) used to confirm the infection. We classified the sources of our data in 6 categories:

- Declared outbreaks
- Single case reports (mainly about returning travelers)

- Surveillance studies, aiming to identify the etiology of acute illnesses confirmed by PCR and/or serology
- Serosurveys (to evaluate previous exposure to the virus, confirmed by serology)
- GenBank sequences, present on the database without additional information on the isolated strains
- Annual report from health authorities.

In this report, experts provided a picture of MAYV geographic spread through Americas; they identified gaps of knowledge and proposed recommendations in order to suggest research priorities in the field.

4. MAYV distribution

An account of the epidemiological findings about MAYV human cases is shown below. Further details are presented in Table 1-5 of Supplementary data (Central America, Caribbean, Brazil, Peru and rest of South America).

I. Central America

A. Mexico

1) Surveillance study

The study was performed on patients with probable diagnosis of DENV in 2001 [13]. 2 cases were found positive with ELISA IgM, one from northern Mexico (Tamaulipas state), the other from western Mexico (Veracruz state).

B. Panama

1) Serosurvey

Serosurvey conducted retrospectively on samples collected during the construction of canals in Panama and Colombia in 1904-1914 [14].

2) Surveillance study

During an encephalitis outbreak in 2010, a household study was performed testing sera for several arboviruses [15]. One case was positive with ELISA IgM in Darien region (southern Panama).

II. Caribbean

A. Haiti

1) Case report

One MAYV strain isolated in 2014 from a patient co-infected with CHIKV living in rural Haiti [5].

2) Case report

Acute case confirmed in 2015 by virus isolation in a patient living in the western part of Haiti [4].

3) Outbreak (NOT CONFIRMED)

Febrile undiagnosed fever suspected of being caused by MAYV in 2018 according to clinical presentation, not supported by biological evidence (ProMED: 20180909.6018117).

B. Trinidad and Tobago

1) Outbreak

First isolation of MAYV during an outbreak of febrile illness in 1954 [1].

2) GenBank sequence (no additional information)

2 MAYV strains isolated in 1957, both belonging to genotype D. GenBank accession numbers available in Table 2-Supplementary data.

III. Brazil

1) Outbreak

A MAYV outbreak was detected in Pará state, northern Brazil, among forest workers [16]. 6 MAYV strains were isolated.

2) Serosurvey

Antibodies against MAYV were detected in sera from Indians living in the Amazon Basin in Mato Grosso state when tested with HI test in 1963-1964 [17].

3) Serosurvey

Sera from military troops in different areas of the country were tested by HI and VNT in 1964 [18]. 1% of samples was positive for antibodies against MAYV.

4) Serosurvey

The survey was performed on sera collected from tribes living in the Amazon Basin, Brazil [19]. Sera were tested by HI test, with 42% of positive rate.

5) GenBank sequence (no additional information)

Two MAYV strains isolated in 1970, both belonging to genotype D. GenBank accession numbers available in Table 3- Supplementary data.

6) Outbreak

MAYV outbreak was detected in a small village in Pará state, northern Brazil, in 1977-1978 [20, 21]. It was estimated that 20% of the 4,000 inhabitants were infected.

7) GenBank sequence (no additional information)

3 MAYV strains isolated in 1981, all belonging to genotype D. GenBank accession numbers available in Table 3- Supplementary data.

8) GenBank sequence (no additional information)

2 MAYV strains isolated in 1984-1988, both belonging to genotype L. GenBank accession numbers available in Table 3- Supplementary data.

9) GenBank sequence (no additional information)

6 MAYV strains isolated in 1991. 5 belong to genotype D, one to genotype L. GenBank accession numbers available in Table 3- Supplementary data.

10) Case report

Three MAYV cases were detected in the state of Mato Grosso, western Brazil, in 2000 [22]. Samples were tested by haemagglutination inhibition test (HI).

11) Case report

The infection was acquired in Acre state, north western Brazil, in 2004 and detected by PCR [23].

12) Surveillance study

Survey of acute febrile illness in Manaus, northern Brazil, in 2007-2008 [24]. 33 cases were confirmed by ELISA IgM, and in one of them viral genome was detected by PCR.

13) Outbreak

The outbreak was detected in a very small village in Pará state, northern Brazil, in 2008 [25]. Cases were diagnosed by ELISA IgM, and 3 MAYV strains were isolated.

14) Case report

Imported case- France ex Brazil, 2009 [26]. The patient was infected in Amazonas state, northern Brazil. ELISA detected presence of IgM in the serum of the patient.

15) Surveillance study

During a large DENV outbreak in the state of Mato Grosso (2011-2012), some DENV- samples from acute febrile patients tested positive by PCR for MAYV [27].

16) Surveillance study

Seroprevalence study conducted in Goiás state, central Brazil, in 2011-2013. DENV- patients were tested with an enzyme immunoassay on infected cultured cells (EIA-ICC) [28].

17) Case report

Imported case- The Netherlands ex Brazil, 2013 [29]. After a travel in Pará state, northern Brazil, the patient tested positive for anti-MAYV IgM and IgG by IFT; the result was confirmed by VNT.

18) Case report

One MAYV infection was acquired in Pará state, northern Brazil, in 2014 [30]. Virus was detected by PCR and isolated.

19) Surveillance study

Study performed in 2014-2015 on CHIKV- patients from Goiás state (central Brazil), tested for anti-MAYV IgM by ELISA [31].

20) Outbreak

MAYV cases were detected in Goiás state, central Brazil, in 2015 (ProMED: 20150705.3485723).

21) GenBank sequence (no additional information)

Virus isolated from human serum in Mato Grosso state, western Brazil, in 2015, belonging to genotype L. GenBank accession number available in Table 3- Supplementary data.

22) Surveillance study

The survey was performed in Mato Grosso state, western Brazil, on samples from acute febrile patients in 2015-2016 [32]. Cases were detected by PCR.

23) Surveillance study

The study was conducted in Amazonas state in 2016 testing samples from patients with acute febrile illness (ProMED: 20161128.4658296).

IV. Peru

1) GenBank sequence (no additional information)

8 MAYV strains isolated in 1995, all belonging to genotype D. GenBank accession numbers available in Table 4- Supplementary data.

2) Case report

Cases of MAYV infection reported from different sites in Peru in 1995-1998 [33]. 25 cases were detected during seroepidemiological studies on surveillance of acute febrile illnesses; 2 were imported cases (USA ex Peru). MAYV was isolated from 21 patients, 6 were diagnosed by serology.

3) GenBank sequence (no additional information)

18 MAYV strains isolated in 1995-2000, all belonging to genotype D. GenBank accession numbers available in Table 4- Supplementary data.

4) Surveillance study

Study performed on samples from febrile patients from different sites in Peru in 2000-2007 [34]. 73 cases were confirmed by virus isolation, PCR or IgM seroconversion. 77 additional cases were classified as presumptive cases (high IgM without seroconversion). 25 MAYV strains were isolated.

5) GenBank sequence (no additional information)

12 MAYV strains isolated in 2002-2006, all belonging to genotype D. GenBank accession numbers available in Table 4- Supplementary data.

6) GenBank sequence (no additional information)

One MAYV strain isolated in 2010, classified as genotype N. GenBank accession number available in Table 4- Supplementary data.

7) Surveillance study

Study performed on sera of febrile patients from different sites of Peru in 2010-2012 [7]. Positive cases were confirmed by virus isolation and/or PCR and/or ELISA IgM.

8) GenBank sequence (no additional information)

3 MAYV strains isolated in 2011, all belonging to genotype D. GenBank accession numbers available in Table 4- Supplementary data.

9) Case report

Imported case- Switzerland ex Peru, after a travel in northern Peru in 2011 [35]. Anti-MAYV IgM and IgG were detected by IF test and diagnosis was confirmed by VNT.

10) Case report

Imported case- Canada ex Peru, 2018. Viral genome was detected by PCR (ProMED: 20180518.5804085).

11) Annual report from health authorities

For the year 2018, Peruvian Health authorities declared 35 MAYV cases (ProMED: 20190503.6454329).

V. Rest of South America

A. Bolivia

1) Outbreak

An epidemic of jungle fever was detected in eastern Bolivia in 1955. 192 people got infected; MAYV was responsible for 10-15% of the cases [36].

2) Case report

One case of MAYV infection was detected in 1999 and confirmed by serological test [10].

3) Surveillance study

The study was performed in 2000-2007 on samples from febrile patients from different sites in Bolivia [34]. 24 cases were confirmed by virus isolation, PCR or IgM seroconversion. 22 additional cases were classified as presumptive cases (high IgM without seroconversion). 15 MAYV strains were isolated.

4) GenBank sequence (no additional information)

10 MAYV strains were isolated in 2002-2006, belonging to genotype D. GenBank accession numbers available in Table 5- Supplementary data.

5) Case report

Case report- Germany ex Bolivia, 2012 [37]. The patient probably got infected in Rurrenabaque region (norther Bolivia). Immunofluorescence test (IFT) and seroneutralization test were used to diagnose MAYV.

6) Case report

Case report- Germany ex Bolivia, 2014 [38]. Immunofluorescence test (IFT) was positive for IgG anti-MAYV; result was confirmed by virus neutralization test (VNT).

B. Colombia

1) Serosurvey

Serosurvey conducted retrospectively on samples collected during the construction of canals in Panama and Colombia in 1904-1914 [14].

2) Serosurvey

Seroprevalence study conducted in Santander state, northern Colombia, in 1959 [39]. Samples were tested by HI.

3) Serosurvey

Seroprevalence study performed in different sites of Colombia in 1966 [40]. Samples from military recruits were tested by HI test.

C. Ecuador

1) Serosurvey

Seroprevalence study performed in south-eastern Ecuador in 1997 [41]. People native to rainforest had higher IgG prevalence (46,2%) compared to people from coastal or mountain areas (2,4%). Samples were tested with ELISA.

2) Surveillance study

Study performed on samples from febrile patients from western Ecuador (2000-2007) [34]. 1 case was confirmed by PCR or IgM seroconversion.

3) Case report

Imported case- Germany ex Ecuador, after a travel in the jungle in 2014 [38]. IF test was positive for both IgM and IgG anti-MAYV.

D. French Guiana

1) Case report

A febrile patient tested positive by HI and ELISA IgM in 1995; the virus was isolated [42].

2) Serosurvey

Sera from different areas of the country were tested with HI test in 1995-1996 [42].

3) GenBank sequence (no additional information)

4 MAYV strains isolated in 1996-1998, belonging to genotype D. GenBank accession numbers available in Table 5- Supplementary data.

4) Case report

Imported case- Germany ex French Guiana, 2013. IgM and IgG anti-MAYV were detected by IF test, and PCR was positive [43].

5) Case report

Imported case- France ex French Guiana, after a travel in the eastern part of the country in 2015. Diagnosis of MAYV infection was confirmed by PCR and ELISA IgM and IgG [44].

E. Suriname

1) Serosurvey

Seroprevalence study conducted on Dutch soldiers stationed in Suriname in 1984 [45].

2) Case report

Imported cases- The Netherlands ex Suriname, after a travel in the central part of the country, 2008 [6]. IgG were detected by ELISA in both patients, IgM in one patient only. The infection was confirmed by VNT.

F. Venezuela

1) Serosurvey

Seroprevalence study performed in northern Venezuela in 1965 [46]. Samples were tested with HI and VNT.

2) Case report

Four cases of MAYV infection in Central Venezuela, 2000. Tested by ELISA, 3 patients were positive for IgM anti-MAYV and all of them had IgG anti-MAYV (ProMED: 20010428.0825).

3) Outbreak

Outbreak detected in Portuguesa state, north western Venezuela, in 2010 [47].

5. Discussion

According to the 9th report of the International Committee on Taxonomy of Viruses (ICTV) [48], MAYV belongs to the Semliki Forest complex and is related to Una virus, previously considered a subtype of MAYV [48]. MAYV strains have been classified, on the basis of E1-E2 partial sequences, into three genotypes: (1) genotype D, largely distributed in South America; (2) genotype L, supposedly limited to Brazil but recently detected in Haiti, and (3) genotype N, a newly described clade accounting for just one MAYV strain isolated in Peru in 2010 [47]. We performed a phylogenetic analysis using 56 MAYV complete genomes and we observed the same subdivision (Figure 3). Genotype D includes several clades that segregated by geographic region (Venezuelan, Peruvian, Bolivian and Brazilian clades); all these isolates are highly conserved (< 3% nucleotide divergence) but are quite distinct from the other genotype isolates (5-6% nucleotide divergence with genotype N and 12-13% nucleotide divergence with genotype L). The wide distribution of genotype D is in contrast to the apparent restriction of genotype L to Brazil. This may be explained by a sampling bias rather than the existence of a specific barrier to MAYV dispersal. It would be of interest to investigate other factors that could be part of genotypic segregation, such as vector competence, vector distribution or presence of alternative amplification

hosts. Of note, no clear epidemiological (apart from geographical distribution), clinical or ecological patterns have been associated to date with the different genotypes. This obviously deserves further investigations.

Mayaro virus circulation has been documented only in the Americas. Data about MAYV cases in humans provide a picture of the regular spill over events leading to human infections in Central and South America in the last 65 years. The Amazon region of Brazil provides the higher number of sporadic cases and epidemics, followed by Peru and Bolivia. This is not surprising, because these countries share borders with Brazilian regions where MAYV has been more frequently detected (Amazonas, Acre and Mato Grosso States). Returning travellers got infected after stays in several countries such as Ecuador, Suriname and French Guiana providing evidence of virus circulation [6, 38, 43, 44]. Data from Central America (Panama, Costa Rica, Guatemala) are outdated and should be updated to reflect the recent circulation of the virus in the area. This is valid also for the Caribbean, especially after a recent report of two cases in Haiti [4, 5]. Overall, seroprevalence and surveillance studies are urgently needed in both Central and South America to better assess the actual scale of MAYV diffusion.

Several factors may have contributed to underestimating the actual prevalence of MAYV infections in humans. First, the widespread circulation of pathogens with an overlapping clinical picture such as dengue virus (DENV), Zika virus (ZIKV) and CHIKV in the American continent, makes probable that MAYV infections have commonly been underreported. Cases of MAYV have been observed during DENV outbreaks or in patients with DENV-like illness, highlighting the fact that similar symptoms make several other arboviral diseases indistinguishable without laboratory testing. In addition, MAYV RT-PCR diagnosis remains poorly available and the cross-reactivity observed between antibodies against MAYV and the closely-related alphaviruses (especially viruses belonging to Semliki forest complex) is a significant barrier to specific serological diagnosis.

Second, since epidemiological data on related alphaviruses has been commonly obtained based on serological tests that also detect to a various extent antibodies to MAYV, MAYV infections may be more common than is generally reported [12]. For example, a seroprevalence study performed in the Amazon Valley of Brazil in 1953-1954 revealed that 18.9% of the samples tested by virus neutralization test were positive for Semliki Forest virus (SFV) [49]. Since SFV is confined to Africa and in the same period MAYV was detected in the Amazon Valley [16], it is possible that such "Semliki Forest-positive" sera actually reflected exposure to MAYV or related variants. Cross-reactivity with chikungunya virus (CHIKV) was also observed in MAYV infected returning travellers, which made the diagnosis late and difficult [6, 43].

According to available data on MAYV distribution, experts identified several gaps of knowledge and provided adapted recommendations (Paragraphs 5 and 6). The aim was to identify and suggest research priorities in the field.

6. Gaps of knowledge

A. Entomological and environmental surveillance

Since *Haemagogus* species are the mosquito transmitter of MAYV in the American continent, detailing the spatial distribution of the vector through the continent, especially in border areas between forest and human habitations, is necessary to inform about regions of increased risk for human cases. The different aspects relating to entomology and natural cycle are further developed and discussed in the ongoing report "entomological aspects and vector control" of the GloPID-R chikungunya, o'nyong-nyong and Mayaro virus Working Group.

B. Disease surveillance and epidemiology

In the last 65 years, the circulation of MAYV in central and southern America has been proven through circumscribed outbreaks, sporadic serosurveys and case reports of returning infected travellers. The available information concerning MAYV diffusion is insufficient to assess the actual burden of MAYV in the American continent.

C. Laboratory tests for seroprevalence studies

High-performance serological assays are needed to overcome the issue of antigenic cross-reactivity between member viruses of the Semliki forest virus serocomplex. In particular, the close phylogenetic relationship among MAYV and CHIKV explains why MAYV and CHIKV antibodies commonly cross-react in ELISA or immunofluorescence testing [12]. Moreover, multiple exposures to various alphaviruses reduce specificity to all serological assays including ELISA, HI, CF, and even the gold standard of specificity, seroneutralisation assays [12]. It is doubtful that adapted and routine serological tools and interpretation algorithms are currently available to expedite accurate and large-scale

seroepidemiological studies for MAYV. Better diagnostics are therefore essential to confirm viral transmission.

D. Laboratory algorithm and case definition for clinical care

The current situation is characterized by the absence of a clear laboratory algorithm ensuring that MAYV is part of differential diagnosis in specific cases (*e.g.* dengue like syndrome with negative DENV laboratory testing); there is no discriminatory routine and specialist serological assays for clinical care; there is no international case definition for probable and confirmed MAYV cases.

E. Diagnosis of acute cases

Very few molecular assays are currently available for MAYV detection. Their performances, as well as their adequacy to detect the different MAYV lineages, have not been assessed through comparative studies. No commercial tests exist except for one anti-MAYV ELISA (IgM and IgG) by EUROIMMUN which has not been clinically evaluated. Multiplex molecular and serological tests for discrimination of MAYV and CHIKV in areas of co-circulation are missing, making differential diagnosis a challenging task. Our information about kinetics of viral load are limited and derive just from sera (kinetics in different body fluids have never been investigated). No International Standards (IS) are available and External Quality Assessment (EQAs) have never been organized to evaluate laboratories capacity to diagnose MAYV infection. The different aspects relating to diagnosis of MAYV infection are further developed and discussed in the report "Biological diagnostics" of the GloPID-R chikungunya, o'nyong-nyong and Mayaro virus Working Group [12].

F. Cross-protection

It is unknown whether individuals infected by MAYV or CHIKV are efficiently protected against secondary infection by the other virus, as well as by other clinically related alphaviruses. It is also unknown whether previous infection by MAYV or CHIKV may be responsible for a potentially more severe infection by the other virus as suggested in the case of successive infection by different serotypes of DENV. This remains to be firmly established from humans or from relevant animal models.

G. Natural history

The natural history of MAYV infection is not accurately characterized, as well as the clinical spectrum of the disease, from acute to long-term sequelae. Few case reports and just one longitudinal study documented persisting arthralgia post MAYV infections [6, 7, 10]. Our knowledge on this subject needs to be increased to determine if a “post-MAYV” syndrome exists, similar to the “post-CHIKV” syndrome that includes a variety of long-term (mostly rheumatologic) complications of CHIKV.

H. Molecular epidemiology.

Convenient genotyping and sequencing techniques are needed to assist the development of molecular epidemiology studies. Moreover, clear cut-off of percent identity and criteria allowing a clear classification of MAYV strains into genotypes do not exist.

7. Expert recommendations

A. Entomological and environmental surveillance

It is necessary to determine the pattern of spatial distribution of *Haemagogus* species, to investigate the vector species range involved in MAYV transmission through field studies and laboratory competence studies, and to characterize the natural transmission cycle and animal reservoirs.

B. Disease surveillance and epidemiology

Specific efforts are required to better characterize MAYV circulation and epidemiology at large scale (including clinical epidemiology). MAYV should be more frequently included in molecular proficiency panels for febrile illnesses of unknown origin in the Americas, and seroprevalence studies should be performed. This obviously requires improved diagnostic assays.

C. Laboratory tests for seroprevalence studies

Accurate assays and algorithms allowing to detect IgG antibodies specific to MAYV and to distinguish them from IgG to CHIKV should be developed. At this stage, performing seroneutralization tests is essential for confirmation after performing a screening assay (*e.g.* ELISA, haemagglutination inhibition test or immunofluorescence assay); however, a proportion of samples remains without clear identification, in particular in case of co-circulation of related viruses. Clear interpretation guidelines or new specific assays are required and reference serological standards are needed (possibly produced from non-human primates [12]).

D. Laboratory algorithm and case definition for clinical care

Case definitions (for probable and confirmed cases) and a clear diagnostic laboratory algorithm should be set-up.

E. Diagnosis of acute cases

For diagnosis at the acute stage of the disease, virus co-circulation requires the development of molecular multiplex tools and specific IgM assays to differentiate MAYV from related alphaviruses in the Americas. Viremia kinetics and viral loads in different body fluids should be better documented, as well as the kinetics of immune response. International Standards (IS) should be made available, taking into account the MAYV genetic heterogeneity. Moreover, External Quality Assessments (EQAs) should be organized in order to assess laboratory capacity of detecting MAYV with both molecular and serological tools.

F. Cross-protection

Cross-protection studies between MAYV and related alphaviruses, in particular CHIKV, should be implemented. Moreover, it is necessary to investigate the possible effect of a previous infection by MAYV or CHIKV on a subsequent infection of MAYV. Both aspects could be clarified using samples from naturally exposed humans and experimentally infected non-human primates.

G. Natural history

Natural history of infection should be better investigated. Longitudinal studies would prove useful to identify long-term complications.

H. Molecular epidemiology

Genotyping and sequencing protocols should be selected and proposed in order to quickly identify the lineage of circulating viral strains. The region of the genome that gives the highest information for genotyping should be identified and this choice standardized in order to allow comparisons across laboratories. Cut-off of percent identity should be standardized to define genotype accurately. Moreover, a genomic reference database should be made available similar to those existing for other arboviruses (e.g. the sites of the Virus Variation Resource (Virus Variation) or the Virus Pathogen Resource (Virus Pathogen Database and Analysis Resource). It would allow to store sequence data, gene and protein annotations as well as information about isolation hosts, country and year.

Acknowledgement

Publication fees were covered by the Global Research Collaboration for Infectious Disease Preparedness (GloPID-R).

Journal Pre-proof





Figure 1. Acute MAYV cases in humans confirmed by PCR or virus isolation. Countries (in green) where MAYV infections have been suggested based on HI, VNT, PRNT, IF or ELISA are not classified in the map since cross-reactivity with related alphaviruses may have affected serological assays.



Figure 2. Distribution of MAYV genotypes.



0.02

Figure 3. Phylogenetic analysis of 56 complete MAYV genomes present in GenBank. Neighbor-joining phylogenetic tree was generated with MEGA 6 using Tamura-Nei model (Gamma distribution) with 1000 bootstrap replication. 10,999 sites were included. All positions containing gaps and missing data were eliminated (complete deletion). The best substitution model was selected with jModeltest. Tip labels indicate GenBank accession number, strain name, country and year of isolation (when available).

- [1] Anderson CR, Downs WG, Wattley GH, et al. Mayaro Virus: A New Human Disease Agent. *The American Journal of Tropical Medicine and Hygiene* 1957; 6: 1012–1016.
- [2] Mackay IM, Arden KE. Mayaro virus: a forest virus primed for a trip to the city? *Microbes and Infection* 2016; 18: 724–734.
- [3] Acosta-Ampudia Y, Monsalve DM, Rodríguez Y, et al. Mayaro: an emerging viral threat? *Emerging Microbes & Infections* 2018; 7: 1–11.
- [4] Lednicky J, De Rochars VMB, Elbadry M, et al. Mayaro Virus in Child with Acute Febrile Illness, Haiti, 2015. *Emerging Infect Dis* 2016; 22: 2000–2002.
- [5] White SK, Mavian C, Elbadry MA, et al. Detection and phylogenetic characterization of arbovirus dual-infections among persons during a chikungunya fever outbreak, Haiti 2014. *PLoS Negl Trop Dis*; 12. Epub ahead of print 31 May 2018. DOI: 10.1371/journal.pntd.0006505.
- [6] Hassing R-J, Leparac-Goffart I, Blank SN, et al. Imported Mayaro virus infection in the Netherlands. *Journal of Infection* 2010; 61: 343–345.
- [7] Halsey ES, Siles C, Guevara C, et al. Mayaro Virus Infection, Amazon Basin Region, Peru, 2010–2013. *Emerg Infect Dis* 2013; 19: 1839–1842.
- [8] Thiberville SD, Moyen N, Dupuis-Maguiraga L, et al. Chikungunya fever: Epidemiology, clinical syndrome, pathogenesis and therapy. *Antiviral Research* 2013; 99: 345–370.
- [9] Heath CJ, Lowther J, Noël TP, et al. The Identification of Risk Factors for Chronic Chikungunya Arthralgia in Grenada, West Indies: A Cross-Sectional Cohort Study. *Open Forum Infect Dis*; 5. Epub ahead of print 1 January 2018. DOI: 10.1093/ofid/ofx234.
- [10] Taylor SF, Patel PR, Herold TJS. Recurrent arthralgias in a patient with previous Mayaro fever infection. *South Med J* 2005; 98: 484–485.
- [11] Paniz-Mondolfi AE, Rodriguez-Morales AJ, Blohm G, et al. ChikDenMaZika Syndrome: the challenge of diagnosing arboviral infections in the midst of concurrent epidemics. *Ann Clin Microbiol Antimicrob*; 15. Epub ahead of print 22 July 2016. DOI: 10.1186/s12941-016-0157-x.
- [12] Pezzi L, Reusken CB, Weaver SC, et al. GloPID-R report on Chikungunya, O'nyong-nyong and Mayaro virus, part I: Biological diagnostics. *Antiviral Res.* Epub ahead of print 21 March 2019. DOI: 10.1016/j.antiviral.2019.03.009.
- [13] Navarrete-Espinosa J, Gómez-Dantés H. [Arbovirus causing hemorrhagic fever at IMSS]. *Rev Med Inst Mex Seguro Soc* 2006; 44: 347–353.
- [14] Srihongse S, Stacy HG, Gauld JR. A survey to assess potential human disease hazards along proposed sea level canal routes in Panamá and Colombia. IV. Arbovirus surveillance in man. *Mil Med* 1973; 138: 422–426.
- [15] Carrera J-P, Bagamian KH, Rosa APT da, et al. Human and Equine Infection with Alphaviruses and Flaviviruses in Panamá during 2010: A Cross-Sectional Study of Household Contacts during an Encephalitis Outbreak. *The American Journal of Tropical Medicine and Hygiene* 2018; 98: 1798–1804.

- [16] Causey OR, Maroja OM. Mayaro Virus: A New Human Disease Agent. *The American Journal of Tropical Medicine and Hygiene* 1957; 6: 1017–1023.
- [17] Neel JV, Andrade AHP, Brown GE, et al. Further Studies of the Xavante Indians. *The American Journal of Tropical Medicine and Hygiene* 1968; 17: 486–498.
- [18] Niederman JC, Henderson JR, Opton EM, et al. A NATIONWIDE SERUM SURVEY OF BRAZILIAN MILITARY RECRUITS, 1964: II. ANTIBODY PATTERNS WITH ARBOVIRUSES, POLIOVIRUSES, MEASLES AND MUMPS. *Am J Epidemiol* 1967; 86: 319–329.
- [19] Black FL, Hierholzer WJ, Pinheiro F, et al. Evidence for persistence of infectious agents in isolated human populations. *Am J Epidemiol* 1974; 100: 230–250.
- [20] Pinheiro FP, Freitas RB, Travassos da Rosa JF, et al. An outbreak of Mayaro virus disease in Belterra, Brazil. I. Clinical and virological findings. *Am J Trop Med Hyg* 1981; 30: 674–681.
- [21] da Rosa APAT, Pinheiro FP, LeDuc JW. An Outbreak of Mayaro Virus Disease in Belterra, Brazil: II. Epidemiology*. *The American Journal of Tropical Medicine and Hygiene* 1981; 30: 682–688.
- [22] Coimbra TLM, Santos CLS, Suzuki A, et al. Mayaro virus: imported cases of human infection in São Paulo State, Brazil. *Revista do Instituto de Medicina Tropical de São Paulo* 2007; 49: 221–224.
- [23] Terzian ACB, Auguste AJ, Vedovello D, et al. Isolation and characterization of Mayaro virus from a human in Acre, Brazil. *Am J Trop Med Hyg* 2015; 92: 401–404.
- [24] Mourão MPG, Bastos M de S, de Figueiredo RP, et al. Mayaro Fever in the City of Manaus, Brazil, 2007–2008. *Vector-Borne and Zoonotic Diseases* 2011; 12: 42–46.
- [25] Azevedo RSS, Silva EVP, Carvalho VL, et al. Mayaro Fever Virus, Brazilian Amazon. *Emerg Infect Dis* 2009; 15: 1830–1832.
- [26] Receveur MC, Grandadam M, Pistone T, et al. Infection with Mayaro virus in a French traveller returning from the Amazon region, Brazil, January, 2010. *Eurosurveillance* 2010; 15: 19563.
- [27] Zuchi N, Heinen LB da S, dos Santos MAM, et al. Molecular detection of Mayaro virus during a dengue outbreak in the state of Mato Grosso, Central-West Brazil. *Mem Inst Oswaldo Cruz* 2014; 109: 820–823.
- [28] Costa VG da, Féres VC de R, Saivish MV, et al. Silent emergence of Mayaro and Oropouche viruses in humans in Central Brazil. *International Journal of Infectious Diseases* 2017; 62: 84–85.
- [29] Slegers CAD, Keuter M, Günther S, et al. Persisting arthralgia due to Mayaro virus infection in a traveler from Brazil: Is there a risk for attendants to the 2014 FIFA World Cup? *Journal of Clinical Virology* 2014; 60: 317–319.
- [30] Mota MTO, Vedovello D, Estofolete C, et al. Complete Genome Sequence of Mayaro Virus Imported from the Amazon Basin to São Paulo State, Brazil. *Genome Announc*; 3. Epub ahead of print 25 November 2015. DOI: 10.1128/genomeA.01341-15.
- [31] Brunini S, França DDS, Silva JB, et al. High Frequency of Mayaro Virus IgM among Febrile Patients, Central Brazil. *Emerging Infect Dis* 2017; 23: 1025–1026.

- [32] de Souza Costa MC, Siqueira Maia LM, Costa de Souza V, et al. Arbovirus investigation in patients from Mato Grosso during Zika and Chikungunya virus introduction in Brazil, 2015–2016. *Acta Tropica* 2019; 190: 395–402.
- [33] Tesh RB, Watts DM, Russell KL, et al. Mayaro virus disease: an emerging mosquito-borne zoonosis in tropical South America. *Clin Infect Dis* 1999; 28: 67–73.
- [34] Forshey BM, Guevara C, Laguna-Torres VA, et al. Arboviral Etiologies of Acute Febrile Illnesses in Western South America, 2000–2007. *PLoS Negl Trop Dis*; 4. Epub ahead of print 10 August 2010. DOI: 10.1371/journal.pntd.0000787.
- [35] Neumayr A, Gabriel M, Fritz J, et al. Mayaro Virus Infection in Traveler Returning from Amazon Basin, Northern Peru. *Emerg Infect Dis* 2012; 18: 695–696.
- [36] Schaeffer M, Gajdusek DC, Lema AB, et al. Epidemic jungle fevers among Okinawan colonists in the Bolivian rain forest. I. Epidemiology. *Am J Trop Med Hyg* 1959; 8: 372–396.
- [37] Theilacker C, Held J, Allering L, et al. Prolonged polyarthralgia in a German traveller with Mayaro virus infection without inflammatory correlates. *BMC Infect Dis* 2013; 13: 369.
- [38] Tappe D, Pérez-Girón JV, Just-Nübling G, et al. Sustained Elevated Cytokine Levels during Recovery Phase of Mayaro Virus Infection. *Emerg Infect Dis* 2016; 22: 750–752.
- [39] Groot H, Kerr JA, Sanmartin C, et al. Antibodies to Yellow Fever and Other Arthropod-Borne Viruses in Human Residents of San Vicente de Chucuri, Santander, Colombia*. *The American Journal of Tropical Medicine and Hygiene* 1959; 8: 175–189.
- [40] Evans AS, Casals J, Opton EM, et al. A NATIONWIDE SERUM SURVEY OF COLOMBIAN MILITARY RECRUITS, 1966I. DESCRIPTION OF SAMPLE AND ANTIBODY PATTERNS WITH ARBOVIRUSES, POLIVIRUSES, RESPIRATORY VIRUSES, TETANUS, AND TREPONEMATOSIS. *Am J Epidemiol* 1969; 90: 292–303.
- [41] Izurieta RO, Macaluso M, Watts DM, et al. Hunting in the Rainforest and Mayaro Virus Infection: An emerging Alphavirus in Ecuador. *J Glob Infect Dis* 2011; 3: 317–323.
- [42] Talarmin A, Chandler LJ, Kazanji M, et al. Mayaro virus fever in French Guiana: isolation, identification, and seroprevalence. *Am J Trop Med Hyg* 1998; 59: 452–456.
- [43] Friedrich-Jänicke B, Emmerich P, Tappe D, et al. Genome Analysis of Mayaro Virus Imported to Germany from French Guiana. *Emerg Infect Dis* 2014; 20: 1255–1257.
- [44] Llagonne-Barets M, Icard V, Leparç-Goffart I, et al. A case of Mayaro virus infection imported from French Guiana. *Journal of Clinical Virology* 2016; 77: 66–68.
- [45] Karbaat J. Arthropod-borne virus infections in Dutch soldiers stationed in Surinam. *Trop Geogr Med* 1965; 17: 187–189.
- [46] Jonkers AH, Downs WG, Spence L, et al. Arthropod-Borne Encephalitis Viruses in Northeastern South America. *The American Journal of Tropical Medicine and Hygiene* 1965; 14: 304–308.
- [47] Auguste AJ, Liria J, Forrester NL, et al. Evolutionary and Ecological Characterization of Mayaro Virus Strains Isolated during an Outbreak, Venezuela, 2010. *Emerging Infect Dis* 2015; 21: 1742–1750.

- [48] Genus: Alphavirus - Togaviridae - Positive-sense RNA Viruses. *International Committee on Taxonomy of Viruses (ICTV)*, https://talk.ictvonline.org/ictv-reports/ictv_online_report/positive-sense-rna-viruses/w/togaviridae/872/genus-alphavirus (accessed 12 July 2019).
- [49] Causey OR, Theiler M. Virus Antibody Survey on Sera of Residents of the Amazon Valley in Brazil. *The American Journal of Tropical Medicine and Hygiene* 1958; 7: 36–41.
- [50] Pinheiro FP, LeDuc JW. Mayaro virus disease. In: *The arboviruses: epidemiology and ecology*. Monath TP, 1988, pp. 137–150.
- [51] Powers AM, Aguilar PV, Chandler LJ, et al. Genetic relationships among Mayaro and Una viruses suggest distinct patterns of transmission. *Am J Trop Med Hyg* 2006; 75: 461–469.
- [52] Vieira CJ da SP, Silva DJF da, Barreto ES, et al. Detection of Mayaro virus infections during a dengue outbreak in Mato Grosso, Brazil. *Acta Tropica* 2015; 147: 12–16.

Highlights: (3-5, 125 characters max including spaces)

- Information on MAYV circulation in Central and Southern America are fragmentary.
- Co-circulating pathogens inducing similar symptoms probably cause underreporting of MAYV infections.
- Improvement of serological tools is necessary to have robust seroprevalence data not affected by cross-reactivity.
- Surveillance of febrile illnesses and longitudinal studies are required to describe the natural history of the disease.
- Molecular epidemiology studies, as well as entomological and environmental surveillance, are needed.